구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bimzelx (bimekizumab) |
Overview Company | UCB |
Overview Modality | ANTIBODY |
Overview Target | IL-17A / IL-17F |
Overview Indication | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. |
Positioning Known limitation | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. |
Positioning Development positioning | Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents. |
MoA Mechanism | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. |
MoA Biomarker | PASI/IGA response, hs-CRP in axial disease. |
PK/PD Half-life | ~23 days |
PK/PD Species | Cynomolgus monkey, PASI 90/100, HiSCR in HS, ASAS40 in axSpA |
PK/PD Animal (cat.) | Human, NHP, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Cynomolgus monkey |
Toxicology Major finding | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Toxicology CRS | N/A |
Clinical Safety signal | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Clinical PASI75 | PASI 100 than secukinumab at week 16 and mai |
Clinical Result source | BE RADIANT (NCT03536884) / BE VIVID / BE SURE |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03536884 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bimzelx (bimekizumab) |
Overview Company | UCB |
Overview Modality | ANTIBODY |
Overview Target | IL-17A / IL-17F |
Overview Indication | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. |
Positioning Known limitation | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. |
Positioning Development positioning | Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents. |
MoA Mechanism | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. |
MoA Biomarker | PASI/IGA response, hs-CRP in axial disease. |
PK/PD Half-life | ~23 days |
PK/PD Species | Cynomolgus monkey, PASI 90/100, HiSCR in HS, ASAS40 in axSpA |
PK/PD Animal (cat.) | Human, NHP, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Cynomolgus monkey |
Toxicology Major finding | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Toxicology CRS | N/A |
Clinical Safety signal | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Clinical PASI75 | PASI 100 than secukinumab at week 16 and mai |
Clinical Result source | BE RADIANT (NCT03536884) / BE VIVID / BE SURE |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03536884 |
추천 비교
추천 비교